AstraZeneca spinoff Viela Bio has gone public in an offering that involved existing backers buying some $70m worth of stock, and its share price has since risen 21.7%.

The rare and age-related disease-focused startup emerged from a drug discovery collaboration between Evotec and Apollo Health Ventures, both of which chipped into the round.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Karolinska Institute's Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.

GV has contributed to a $92m series B round for Tenaya, three years after it was spun out of Gladstone Institutes and University of Texas Southwestern Medical Center.

Livzon Pharmaceutical Group has been identified as an investor by MIT spinout Elicio Therapeutics, which just completed a series B round that takes its total financing to $63m.

GV has contributed to a $92m series B for Tenaya, three years after it was spun out of Gladstone Institutes and University of Texas Southwestern Medical Center.

Praktikertjänst-backed Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.

Icosavax has launched with $51m in series A funding from Sanofi Ventures and others to move a vaccine for respiratory syncytial virus into a phase 1b trial.